Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Supernus Pharmaceuticals (SUPN) Current Leases (2020)

Supernus Pharmaceuticals has reported Current Leases over the past 2 years, most recently at $3.7 million for Q3 2020.

Quarterly Current Leases changed N/A to $3.7 million in Q3 2020 from the year-ago period, while the trailing twelve-month figure was $3.7 million through Sep 2020, changed N/A year-over-year, with the annual reading at $2.8 million for FY2019, N/A changed from the prior year.
Current Leases was $3.7 million for Q3 2020 at Supernus Pharmaceuticals, down from $4.2 million in the prior quarter.
Over five years, Current Leases peaked at $4.2 million in Q2 2020 and troughed at $2.8 million in Q4 2019.